Cathelicidin LL-37 Fragments
Overview
Cathelicidin LL-37 fragments are truncated sequences derived from the human antimicrobial peptide LL-37, which is a 37-amino acid cleavage product of the cathelicidin precursor hCAP18. These fragments retain antimicrobial, immunomodulatory, and wound healing properties while potentially offering improved stability or reduced cytotoxicity.
Mechanism of Action
Specific fragments have been designed to preserve angiogenic and chemotactic activities relevant to tissue repair.
Research Summary & Key Findings
In vitro studies have demonstrated that certain LL-37 fragments maintain broad-spectrum antimicrobial activity against bacteria and fungi. Preclinical wound models in rodents have shown acceleration of healing through enhanced re-epithelialization and modulation of inflammatory responses. Clinical development has been limited, with no approved therapeutic applications to date.
Clinical Status
Cathelicidin LL-37 Fragments is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed — "Cathelicidin LL-37 Fragments"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Cathelicidin LL-37 Fragments"
Registered interventional and observational studies, including status and phase.
- PubChem — "Cathelicidin LL-37 Fragments"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Recovery
BPC-157
Research PhaseA synthetic gastric pentadecapeptide derived from a protein found in human gastric juice. BPC-157 promotes angiogenesis ...
View detailsTB-500 (Thymosin Beta-4)
In Clinical TrialsThymosin Beta-4 is a 43-amino acid actin-sequestering protein involved in cell migration, differentiation, and tissue re...
View detailsGHK-Cu
Research PhaseA naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. G...
View detailsDSIP (Delta Sleep-Inducing Peptide)
Research PhaseA naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from cerebral venous blood o...
View detailsStart Your Consultation
Get an AI-proposed Cathelicidin LL-37 Fragments protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Cathelicidin LL-37 Fragments.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.